Vidéo d’info sur les syndromes myélodysplasiques en 2 minutes chrono⏱️ Merci Abbvie France pour cette opportunité

🩸 IDH1/2 mutations in intensively treated #AML: ➡️ NPM1 & DNMT3A co-mutations drive prognosis. ➡️ IDH1/2 persistence in remission does not predict progression. #leusm #AMLsm 🎉⁦@LaureneFenwarth⁩

“To effectively contain a civilization’s development and disarm it across such a long span of time, there is only one way: kill its science.” #The_Three_Body_Problem #Cixin_Liu

The Mavs just traded Luka Doncic and you think you’re irreplaceable at work… 😂😅😅

Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type | EMBO reports https://t.co/9eKIoQ62LT James Manfredi, @RamyRahme and colleagues @IcahnMountSinai

Finally, I started reading The Three-Body Problem trilogy. 😌

This will open the path to a better understanding of the biology of transcriptional regulation by p53 mutants in agressive hematologic malignancies. We’ve got data in leukemia models: let’s hope we’ll be able to publish our forthcoming findings in less than half of a decade! 4/4

We show that missense mutant p53 can regulate gene expression in the hematopoietic system of mice. This unexpected molecular finding supports both the gain-of-function and the selective loss-of-function hypotheses that tend to characterize mutant p53 activities in cancer. 3/4

“Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type" by Ramy Rahmé, Lois Resnick-Silverman, Vincent Anguiano, Moray Campbell, Pierre Fenaux and James Manfredi (Link for paper next month in the next issue of EMBO reports) 2/4

Finally!! After almost 5 years of hard work, our paper on transcriptional regulation by mutant p53 is now accepted for publication in EMBO Reports (IF 8.8)!! What a relief this is!! 😌 😌 😌 1/4

The HARMONY APL project confirms that ATRA/ATO combination significantly improves outcome, regardless of patient age and Sanz risk score. https://t.co/ys6YanZFeB #myeloidneoplasia #clinicaltrialsandobservations

The classification of #AML with #CEBPA mutations has become more complicated with the #ICC and #WHO 2022 updates. 🧑‍⚕️Here are the results of 2 patients with AML and CEBPA mutations in my NGS series today.

Civilizations die because of gossip.

#AI in #Hematology : Where do we stand in 2023? @ #ASH2023 #ASH23

Looking forward to moderating a great line up of speakers in “604 - Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic implications of LSCs and differentiation in myeloid malignancies” in Pacific Ballroom Salon 18-19! #ASH23 #AML #Leukemia #Hematology

Come today between 5:30 & 7:30 PM (Halls G-H) and check our #Abstract No 1520 “Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience”. #ASH23 #SanDiego #Hematology

A bord du TGV INOUI 6109 en direction de Marseille. Le conducteur apporte de la bonne humeur. C’est appréciable ! Un grand merci 🫶🤙@SNCFVoyageurs

Nous recherchons toujours deux CCA pour le service d’Hématologie clinique du CHU Avicenne, Université Sorbonne Paris Nord, à partir de 11/2023. Un poste est à orientation lymphoïde/ambulatoire. Le second est myéloïde/soins intensifs. N’hésitez pas à me contacter 🤙

Le 👄 à 👂 fonctionne bien ! Nous recrutons toujours. N’hésitez pas à me contacter sur Twitter !!

Mais le matou revient le jour suivant, Le matou revient, il est toujours vivant. 🐈‍⬛